Bridgeway Capital Management, LLC Aeglea Bio Therapeutics, Inc. Transaction History

Bridgeway Capital Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.35 - $1.54 $52,500 - $231,000	150,000 New	150,000 $67,000
Q2 2022 Aug 15, 2022	SELL	$0.5 - $2.66 $37,178 - $197,789	-74,357 Reduced 60.45%	48,643 $25,000
Q1 2022 May 16, 2022	BUY	$1.87 - $4.77 $230,010 - $586,710	123,000 New	123,000 $283,000
Q2 2020 Aug 14, 2020	SELL	$4.01 - $11.04 $459,145 - $1.26 Million	-114,500 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$3.51 - $8.48 $42,120 - $101,760	12,000 Added 11.71%	114,500 $534,000
Q3 2018 Nov 13, 2018	BUY	$8.24 - $11.0 $20,600 - $27,500	2,500 Added 2.5%	102,500 $981,000
Q3 2017 Nov 14, 2017	BUY	$2.91 - $4.93 $291,000 - $493,000	100,000	100,000 $474,000

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.